KPRX (Kiora Pharmaceuticals Inc.) יחס שווי שוק לשווי בספרים

The price-to-book ratio for Kiora Pharmaceuticals (KPRX) reflects the current asset valuation, where the parameter value is 0.61. This trend captures the ambition of Kiora Pharmaceuticals to expand its portfolio of treatments for rare ocular pathologies. Revenues are based on the supply of unique drugs to clinics and insurance funds. The development strategy relies on independently bringing products to market through licensing agreements.

This indicator is calculated as the ratio of the total market capitalization of all shares to the sum of net assets reported in the financial statements. It measures the premium investors are willing to pay for the business's future prospects beyond its current assets. For Kiora Pharmaceuticals (KPRX), this premium reflects speculative expectations regarding the outcomes of clinical trials for ophthalmology drugs. By analyzing the ratio of the company's current market price to its balance sheet net assets, one can assess the extent of R&D risks priced into the quotes. The trend of the curve helps identify the point where valuation becomes overheated relative to actual capital.